Clinical Trials Sponsored by ProThera, Inc

Total 35431 results

ProThera, Inc.

Unknown

Efficacy of Myalgesin™ to Support Joint Function in Patients With Knee Osteoarthritis

Osteoarthritis

United States
Protegera, Inc.

Completed

Evaluation and Comparison of a Novel Dentrifice Formulation on Plaque Removal

Dental Plaque

United States
Priothera SAS

Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT (MO-TRANS)

Adult Acute Myeloid Leukemia

Italy, Spain, Israel, Japan, France, Germany, United Kingdom, United States, Switzerland, Romania, Taiwan, Poland, Brazil
Cothera Bioscience, Inc

Recruiting

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphatic Diseases | Burkitt Lymphoma | High-grade B-cell Lymphoma | C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma | C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma | Lymphoma, High-Grade | C-Myc Gene Rearrangement

Korea, Republic of, China
EpicentRx, Inc.
Prothex Pharma, Inc.

Completed

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers (PREVLAR)

Oral Mucositis

United States
Panthera Dental Inc.
AXONAL

Recruiting

Long-term Efficacy, Tolerance and Compliance of Panthera D-SAD® Mandibular Advancement Orthosis in Sleep Apnea (PANTHERA)

Sleep Apnea, Obstructive

France
Prothena Biosciences Ltd.

Terminated

Study in Subjects With Light Chain (AL) Amyloidosis

AL Amyloidosis

United States, Spain, Australia, Italy, Germany, Austria, Greece, France, Israel, United Kingdom
Trethera

Recruiting

Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

Oncology | Solid Tumor, Adult

United States
Prothena Biosciences Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis (AFFIRM-AL)

Light Chain (AL) Amyloidosis

United States, Korea, Republic of, Australia, Denmark, France, Italy, Spain, Israel, Taiwan, Austria, Canada, Czechia, Germany, Greece, Hungary, Japan, Netherlands, Poland, Portugal, Turkey, United Kingdom, Belgium, Ireland
Prothena Biosciences Limited

Terminated

A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Amyloidogenic Transthyretin (ATTR) Amyloidosis

United States, Spain, Sweden, Portugal
Prothena Biosciences Ltd.

Terminated

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis (OLE)

AL Amyloidosis

United States
Prothena Biosciences Ltd.

Completed

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis (PRONTO)

AL Amyloidosis

United States, Spain, Australia, Germany, United Kingdom, France, Greece, Israel, Italy, Austria
Prothena Biosciences Ltd.

Terminated

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis (VITAL)

Primary Systemic (AL) Amyloidosis

United States, Spain, Israel, Canada, Poland, Netherlands, France, Germany, United Kingdom, Belgium, Denmark, Greece, Australia, Austria, Italy
Prothena Biosciences Ltd.

Completed

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Primary Amyloidosis

United States
Prothena Biosciences Limited

Completed

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

Psoriasis

United States
Prothena Biosciences Limited

Completed

Single Ascending Dose Study of PRX003 in Healthy Subjects

Psoriasis

United States
Promethera Therapeutics

Completed

Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) (HEP001)

Urea Cycle Disorders | Crigler Najjar Syndrome

Israel, United Kingdom, Belgium, France, Italy
Promethera Therapeutics

Completed

Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002)

Urea Cycle Disorders

Belgium, Spain, France, Poland
Promethera Therapeutics

Completed

Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF (HEP101)

Acute-On-Chronic Liver Failure

Belgium, France
Promethera Therapeutics

Completed

Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)

Urea Cycle Disorders | Crigler Najjar Syndrome

Belgium
Protara Therapeutics

Recruiting

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age (STARBORN-1)

Lymphatic Malformation

United States
Prothya Biosolutions

Active, not recruiting

Apotransferrin in Atransferrinemia

Congenital Atransferrinemia

Spain, Germany, Italy
Protara Therapeutics

Completed

Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition (THRIVE-1)

Intestinal Failure-associated Liver Disease

United States, Denmark, United Kingdom, Italy
Prothya Biosolutions

Terminated

Apotransferrin in Patients With β-thalassemia

β-thalassemia Intermedia

Netherlands
Promethera Therapeutics

Completed

Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients (PANASH)

NASH - Nonalcoholic Steatohepatitis

Spain, Belgium, Bulgaria, France
Protara Therapeutics

Recruiting

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-1)

Non-muscle Invasive Bladder Cancer

United States
Prothya Biosolutions

Completed

Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy

Myocardial Diseases | Parvovirus B19, Human

Netherlands
Prothya Biosolutions

Completed

C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

Angioedema

Netherlands
Prothya Biosolutions

Completed

Kinetics, Efficacy and Safety of C1-Esteraseremmer-N

Hereditary Angioedema Type I | Angioneurotic Edema

Netherlands
Prothya Biosolutions

Completed

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

Hemophilia B

Netherlands
Prothya Biosolutions

Completed

Efficacy and Safety of IVIG-L in ITP Patients

Purpura, Thrombocytopenic, Idiopathic

Poland
Protara Therapeutics

Recruiting

Dose Expansion, Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-2)

Non-muscle Invasive Bladder Cancer

United States, Ukraine
Protara Therapeutics

Recruiting

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (ADVANCED-1)

Non-muscle Invasive Bladder Cancer

United States, Moldova, Republic of, Romania, Ukraine
Prothya Biosolutions

Completed

Study Use of PPSB-SD and VP-VI in Patients With Anticoagulant Therapy and Undergoing Acute CPB Surgery

CPB | Oral Anticoagulant Therapy

Belgium
Prothya Biosolutions

Completed

Pharmacokinetics of New HepBQuin

Healthy

Germany
Prothya Biosolutions

Completed

Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml (Nanogam)

Primary Immunodeficiency

Netherlands
Prothya Biosolutions

Completed

Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response (Subklasse)

Infections | IgG Deficiency

Netherlands
Prothya Biosolutions

Completed

C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

Angioedema

Netherlands
Prothya Biosolutions

Completed

Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients

Hypogammaglobulinemia

Netherlands
Othera Pharmaceuticals

Terminated

Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal

Epiretinal Membrane | Macular Hole

United States
Othera Pharmaceuticals

Unknown

The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD) (OMEGA)

Age-Related Macular Degeneration

United States
Hoffmann-La Roche
Prothena Biosciences Limited

Active, not recruiting

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA)

Parkinson's Disease

United States, Spain, France, Germany, Austria
Hoffmann-La Roche
Prothena Biosciences Limited

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

Parkinsons Disease

United States, United Kingdom, Canada, France, Luxembourg, Poland, Spain, Italy, Austria
Prothena Biosciences Limited
Hoffmann-La Roche

Completed

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

Parkinson's Disease

United States
Prothena Biosciences Limited
Hoffmann-La Roche

Completed

Single Ascending Dose Study of PRX002 in Healthy Subjects

Parkinson's Disease

United States
Othera Pharmaceuticals

Completed

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

Ocular Hypertension | Glaucoma, Open-Angle

United States
Brothers Hospitallers Hospital in Cracow
Jagiellonian University

Recruiting

Effect of Laparoscopic Cholecystectomy on Risk of Metabolic Syndrome

Metabolic Syndrome | Cholelithiasis

Poland
UMC Utrecht
Prothya Biosolutions

Terminated

Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture (CAESAR)

Sepsis | Inflammation | Trauma | Multiple Organ Dysfunction Syndrome

Netherlands
Corthera, Inc.(formerly BAS Medical, Inc.), a member...

Terminated

Recombinant Human Relaxin for the Treatment of Decompensated CHF

Congestive Heart Failure (CHF)

Russian Federation
Corthera, Inc.(formerly BAS Medical, Inc.), a member...

Completed

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF)

Heart Failure, Congestive

United States, Israel

Clinical Trials Sponsored by ProThera, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations